



A Guide to Managing **Donor Sites**



Makers of V.A.C.[®] Therapy

The Painful Second Wound

Focus is often placed on a successful skin graft site. But harvesting for a graft creates a second wound with its own challenges - the donor site wound. It has been reported that pain and discomfort occur more often in donor site wounds than in the actual graft recipient site.¹

The Ideal Dressing

Finding dressings that address the needs of donor site wounds can be challenging to clinicians.² Using **PROMOGRAN PRISMA**[™] Matrix as a primary dressing provides many advantages for both patient comfort and improved outcomes.

In a global online survey, clinicians stated the following characteristics were either essential or desirable in a donor site wound dressing:²

| % OF CLINICIANS THAT AGREED: | DRESSING CHARACTERISCTICS ⁴ | PROMOGRAN PRISMA [™] MATRIX PROVIDES: | |
|------------------------------------|---|---|--|
| 98.5 % ^{2,A} | Pain-free dressing changes | Composite of 44% oxidized regenerated cellulose (ORC), 55% Collagen, and 1% silver-ORC | |
| 92.7 % ^{2,B} | Ease of removal | When in contact with fluid the matrix gels to contact the wound bed and does not require removal of any residual material ³ | |
| 88 % ^{2,C} | Lack of adhesion to the wound bed | | |
| 86.9% ^{2,D} | Absorbancy | Helps manage exudate levels in conjunction with an appropriate secondary/cover dressing ⁴ | |
| 68 % ^{2,E} | Reduction of blood loss | Has hemostatic properties ⁴ | |
| 43 % ^{2,F} | Antimicrobial activity | Helps prevent infection and does not delay healing⁵ Lowers pH level⁶ Has antimicrobial properties^{4,8} | |

Footnotes:

A. Calculation of 98.5% based on response of "essential" 55.1% (n=38) and "desirable" 43.5% (n=30), N=69. B. Calculation of 92.7% based on response of "essential" 53.6% (n=37) and "desirable" 39.1% (n=27), N=69. C. Calculation of 88% based on response of "essential" 39.1% (n=27) and "desirable" 43.5% (n=30), N=69. D. Calculation of 86.9% based on response of "essential" 39.1% (n=27) and "desirable" 47.8% (n=33), N=69. E. Calculation of 68% based on response of "essential" 39.1% (n=27) and "desirable" 47.8% (n=33), N=69. E. Calculation of 68% based on response of "essential" 28.9% (n=20) and "desirable" 39.1% (n=27), N=69. E. Calculation of 43% based on response of "essential" 15.9% (n=11) and "desirable" 27.5% (n=19), N=69.

"The majority of **respondents preferred a wound dressing that required no dressing change** until the donor site had healed in order to improve healing by minimizing wound surface irritation. Avoiding frequent trauma of the regenerating epithelium during dressing change seemed to be pivotal. In addition, **the potential to minimize patient discomfort** with fewer dressing changes can improve patients' compliance, and consequently **permit earlier patient discharge**, resulting in a reduced length-of-stay with possible financial implication for inpatient care."²

Because they do not need to be removed from the donor site wound, PROMOGRAN PRISMA[™] Matrix dressings may minimize trauma to the regenerating epithelium.^{2,3}

Why Use Collagen/ORC vs. Collagen-Only Dressings?

In vitro studies have shown that the combination of collagen and ORC (Oxidized Regenerated Cellulose) has a greater effect in reducing both MMP and elastase activity than collagen alone.^{7,8} ORC has been found to reduce elastase activity, as well as the activities of other proteases.⁹ Furthermore, as ORC degrades, it lowers the pH which has been shown in vitro to help control bacterial growth.¹⁰



ACELITY[™] Primary and Cover Dressing Application Instructions

- 1. Follow institutional protocol to prepare the wound bed
- 2. Assess the level of exudate and apply PROMOGRAN PRISMA[™] Matrix: For minimal to low exudate moisten the matrix with saline to initiate transformation into gel
- 3. Cover with an appropriate cover dressing from the TIELLE[™] Dressings Family per clinician preference, such as: TIELLE[™] Non Adhesive Hydropolymer Dressing with LIQUALOCK[™] Technology or TIELLE[™] Silicone Border Hydropolymer Dressing with Silicone with LIQUALOCK[™] Technology
 - If TIELLE[™] Non Adhesive Dressing is used, secure in place with an appropriate secondary dressing
- 4. Reapply PROMOGRAN PRISMA[™] Matrix:

It is not necessary to remove any residual PROMOGRAN PRISMA[™] Matrix during dressing changes. When product is no longer visible, reapply per clinician recommendation

Consider using ADAPTIC TOUCH[™] Non-Adhering Silicone Dressing if pain during dressing change is a concern.

| PROMOGRAN PRISMA [™] Matrix | | | | |
|--|----------------------|------------|------------|--|
| Size | UOM packaged | SKU | HCPCS code | |
| 4.34 sq. in Hexagon | 10 eaches/CT 4 CT/BX | MA028 | A6021 | |
| 19.1 sq. in Hexagon | 10 eaches/CT 4 CT/BX | MA123 | A6022 | |
| TIELLE [™] Non-Adhesive Hydropolymer Dressing with LIQUALOCK [™] Technology | | | | |
| Size | UOM packaged | SKU | HCPCS code | |
| 2" x 2" | 10 eaches/CT 5 CT/BX | TLN0505EN | A6209 | |
| 4" x 4" | 10 eaches/CT 5 CT/BX | TLN1010EN | A6209 | |
| 6" x 6" | 10 eaches/CT 5 CT/BX | TLN1515EN | A6210 | |
| | 5 eaches/CT 5 CT/BX | TLN1717EN | A6211 | |
| 8" x 8.6" | 5 eaches/CT 5 CT/BX | TLN2122EN | A6211 | |
| TIELLE [™] Silicone Border Hydropolymer Dressing with Silicone with LIQUALOCK [™] Technology | | | | |
| 2 ³ / ₄ " x 3 ¹ / ₂ " | 10 eaches/CT 5 CT/BX | TLSB0709EN | A6212 | |
| 4" x 4" | 10 eaches/CT 5 CT/BX | TLSB1010EN | A6212 | |
| 5" x 5" | 10 eaches/CT 5 CT/BX | TLSB1212EN | A6212 | |
| 7" x 7" | 10 eaches/CT 5 CT/BX | TLSB1717EN | A6213 | |
| 8 ¹ / ₄ " x 8 ⁵ / ₈ " | 10 eaches/CT 5 CT/BX | TLSB2122EN | A6213 | |
| ADAPTIC TOUCH [™] Non-Adhering Silicone Dressing | | | | |
| Size | UOM packaged | SKU | HCPCS code | |
| 2 " x 3 " | 10 eaches/CT 5 CT/BX | 500501 | A6206 | |
| 3 " x 4 ¹ / ₄ " | 10 eaches/CT 5 CT/BX | 500502 | A6206 | |
| 5 " x 6 " | 10 eaches/CT 5 CT/BX | 500503 | A6207 | |
| 8 " x 12 ¹ / ₄ " | 10 eaches/BX | 500504 | A6208 | |

To learn more about the benefits PROMOGRAN PRISMA[™] Matrix and TIELLE[™] Non-Adhesive Dressings, call 800-275-4524 or visit acelity.com

References:

- Beldon P. What you need to know about skin grafts and donor site wounds: Technical guide. Wound Essentials. 2007;2:149-155. http://www.woundsinternational.com/media/issues/231/files/content_196.pdf. Accessed: May 9, 2017.
- 2. Lars PK, Giretzlehner M, Trop M, et al. The properties of the "ideal" donor site dressing: results of a worldwide online survey. Annals of Burns and Fire Disasters. 2013;26(3):136-141.
- PROMOGRAN PRISMA[®] Matrix [Indications for Use package insert]. Gargrave, North Yorkshire, UK: Systagenix Wound Management, Limited; 2011.
 Cullen B, Ivins N. PROMOGRAN & PROMOGRAN PRISMA made easy. Wounds International. 2010;1(3).

- 5. Gottrup F, Cullen B, et al. Randomized controlled trial on collagen/oxidized regenerated cellulose /silver treatment. Wound Repair & Regeneration. 2013; 21(2):216-25. doi:10.1111/wrr.12020.
- 6. Greener B, Hughes AA, Bannister NP, Douglass. Proteases and pH in chronic wounds. J Wound Care. 2005; 14(2):59-61
- Cullen B, et al. The role of oxidized regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action. Int J Biochem Cell Biol. 2002;34(12):1544-1556.
 Gibson M, Cullen B. Can natural materials be adapted to optimize their efficacy in wound care? Poster presented at: Symposium on Advanced Wound Care (SAWC); October 16-18, 2014; Las Vegas, NV.

http://www.systagenix.net/media/originals/20150107-173007-6795.pdf. Accessed May 25, 2017.

9. Cullen B, et al. Modulation of the chronic wound environment; an in vitro evaluation of advanced wound therapies. Poster presented at: Symposium of Advanced Wound Care (SAWC); April 28-May 1, 2007; Tampa, FL. 10. Dineen P. Antibacterial activity of oxidized regenerated cellulose. Surg Gynecol Obstet. 1976;142(4):481-6..

NOTE: Specific indications, contraindications, warnings, precautions and safety information may exist for Systagenix products. Please consult a healthcare provider and product instructions for use prior to application. Rx only.

Copyright 2017 KCI Licensing, Inc. and Systagenix Wound Management, Limited. All rights reserved. All trademarks designated herein are proprietary to KCI Licensing, Inc. and Systagenix Wound Management, Limited, its affiliates and/or licensors. LIT#29-A-327 • PRA000936-R0-US, EN (06/17)



